274 related articles for article (PubMed ID: 19998243)
21. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
22. [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].
Vrbíková J; Hill M; Stárka L; Cibula D; Snajderová M; Sulcová J; Vondra K; Bendlová B
Cas Lek Cesk; 2001 Nov; 140(22):688-94. PubMed ID: 11789058
[TBL] [Abstract][Full Text] [Related]
23. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
24. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
25. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Kilicdag EB; Bagis T; Zeyneloglu HB; Tarim E; Aslan E; Haydardedeoglu B; Erkanli S
Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
[TBL] [Abstract][Full Text] [Related]
26. Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile.
Aghahosseini M; Aleyaseen A; Safdarian L; Moddaress-Hashemi S; Mofid B; Kashani L
Arch Gynecol Obstet; 2010 Dec; 282(6):691-4. PubMed ID: 20596715
[TBL] [Abstract][Full Text] [Related]
27. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
Glueck CJ; Goldenberg N; Sieve L; Wang P
Metabolism; 2008 Jul; 57(7):954-60. PubMed ID: 18555837
[TBL] [Abstract][Full Text] [Related]
28. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
Maciel GA; Soares Júnior JM; Alves da Motta EL; Abi Haidar M; de Lima GR; Baracat EC
Fertil Steril; 2004 Feb; 81(2):355-60. PubMed ID: 14967373
[TBL] [Abstract][Full Text] [Related]
29. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
[TBL] [Abstract][Full Text] [Related]
30. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
Pawelczyk L; Spaczynski RZ; Banaszewska B; Duleba AJ
Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):209-13. PubMed ID: 15063962
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome.
Tolino A; Gambardella V; Caccavale C; D'Ettore A; Giannotti F; D'Antò V; De Falco CL
Eur J Obstet Gynecol Reprod Biol; 2005 Mar; 119(1):87-93. PubMed ID: 15734091
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
Trolle B; Flyvbjerg A; Kesmodel U; Lauszus FF
Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923
[TBL] [Abstract][Full Text] [Related]
33. Effects of metformin on endocrine, metabolic milieus and endometrial expression of androgen receptor in patients with polycystic ovary syndrome.
Ito-Yamaguchi A; Suganuma R; Kumagami A; Hashimoto S; Yoshida-Komiya H; Fujimori K
Gynecol Endocrinol; 2015 Jan; 31(1):44-7. PubMed ID: 25237893
[TBL] [Abstract][Full Text] [Related]
34. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
Tang T; Glanville J; Hayden CJ; White D; Barth JH; Balen AH
Hum Reprod; 2006 Jan; 21(1):80-9. PubMed ID: 16199429
[TBL] [Abstract][Full Text] [Related]
35. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.
Morin-Papunen LC; Koivunen RM; Ruokonen A; Martikainen HK
Fertil Steril; 1998 Apr; 69(4):691-6. PubMed ID: 9548159
[TBL] [Abstract][Full Text] [Related]
36. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
37. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome.
Sönmez AS; Yasar L; Savan K; Koç S; Ozcan J; Toklar A; Yazicioğu F; Akgün A; Sut N
Hum Reprod; 2005 Jan; 20(1):175-9. PubMed ID: 15513975
[TBL] [Abstract][Full Text] [Related]
39. [Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome].
Pekhlivanov B; Mitkov M; Kavŭrdzhikova S
Akush Ginekol (Sofiia); 2006; 45(6):29-35. PubMed ID: 17168480
[TBL] [Abstract][Full Text] [Related]
40. The value of sex hormone binding globulin (SHBG) in predicting treatment response in polycystic ovary syndrome (PCOS).
Wassell J; Michail M; Soliman N; Wardle PG
Clin Lab; 2011; 57(1-2):95-8. PubMed ID: 21391472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
